Abstract
Given extensive reports of anticancer nanomedicines in preclinical studies, why is there such a paucity of clinical trials using these therapies? Nanotechnology can certainly deliver, but we need to tackle the limitations that are impeding the translation of nanomedicines into the clinic and start benefiting from their full potential.
Original language | English |
---|---|
Pages (from-to) | 730-732 |
Journal | Trends in Cancer |
Volume | 6 |
Issue number | 9 |
Early online date | 16 May 2020 |
DOIs | |
Publication status | Published - Sept 2020 |
Keywords
- biomaterials
- cancer therapy
- clinical translation
- nanomedicine